Navigation Links
Weikang Bio-Technology Group Co., Inc. Announces Fiscal Year 2011 Financial Results

HARBIN, China, April 2, 2012 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (WKBT.PK)("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced its financial results for fiscal year ended December 31, 2011. Summary financial data is provided below:

Fiscal Year 2011 Financial Highlights

  • Net sales for the fiscal year ended December 31, 2011 increased by 36% to $101.68 million, up from $74.55 million for the same period last year.
  • Net income for the fiscal year ended December 31, 2011 was $29.63 million, as compared to $24.44 million for the fiscal year ended December  31, 2010.
  • Gross margin for the fiscal year ended December 31, 2011 decreased to 59% based on gross profit of $59.59 million, as compared to a 60% margin in the same period of 2010.
  • Earnings per diluted share were $0.90 for the fiscal year 2011, as compared to $0.87 for the same period of 2010.

Mr. Yin Wang, Chairman and CEO of Weikang stated: "We are thrilled by the financial results of fiscal year of 2011. Our growth strategy continues to prove successful, as evidenced by our strong performance in the fiscal year of 2011. Although we are facing severe competition within TCM industry and slowdown of the Chinese economy, we still achieved the best performance in our company's history. In the next few years," Mr. Wang continued, "we will continue to execute our organic growth strategy while pursuing expansion through acquisition. As a matter of fact the slowdown of the Chinese economy gives us more opportunities in selecting acquisition targets, which we believe will put us on strong footing to continue our growth."

Results of Operations for the fiscal year ended December 31, 2011

Net sales

Net sales for the year ended December 31, 2011 were $101.68 million, compared to $74.55 million for the year ended December 31, 2010, an increase of $27.13 million or 36%.  Increase in units of products sold for the year ended December 31, 2011 accounted for approximately 75% of increase in sales primarily due to 1) the production and sales of new products starting in the third quarter of 2010, which brought us approximately $7.80 million sales revenue during the year of 2011; and 2) a six-month promotion plan starting from the fourth quarter of 2010 to the end of first quarter of 2011, which is the peak season for sales of health care products in the PRC due to the Chinese New Year Holiday and Chinese tradition of having tonic in winter. The remaining 25% increase in sales was attributable to the increase in unit sales price for certain highly demand products, such as Ferrous Fumarate Granule, Eucommia Ulmoides Oliv Granule, Tinidazole Vaginal Effervescent Tablet, Bushen Qiangshen Tablet, and Ranitidine Hydrochloride Capsule.

Gross profit

Gross profit was $59.59 million for the year ended December 31, 2011, compared to $45.02 million for the comparable period of 2010, our gross margin was 59% and 60% of sales for the year ended December 31, 2011 and 2010, respectively. The decrease in our gross profit margin for the year ended December 31, 2011 was mainly due to increase in cost of goods sold resulting from increase taxes for cost of goods sold.

Net income

Net income for the year ended December 31, 2011 was $29.63 million compared to $24.44 million for the same period of 2010, an increase of $5.19 million or 21%.  The increase was mainly attributable to increase in net sales.

Liquidity and Capital Resources

At December 31, 2011, the Company had cash and equivalents of $70.78 million, other current assets of $11.06 million, and current liabilities of $7.56 million. In addition, at December 31, 2011, working capital was $40.50 million and the ratio of current assets to current liabilities was 19.79-to-1.

Net cash provided by operating activities was $30.45 million for the year ended December 31, 2011, compared to $34.19 million for the same period of 2010. The decrease in net cash inflow from operating activities was mainly due to a significant increase in accounts receivable outstanding as a result of the increase in sales, prepayment to suppliers and inventory, despite of the increase in net income.

Net cash used in investing activities was $15.03 million for the year ended December 31, 2011, compared to cash used in investing activities of $0.73 million for the year ended December 31, 2010.  The cash outflow during the year ended December 31, 2011 was mainly due to purchase of a new workshop building and acquisition of manufacturing equipment.

Net cash provided by financing activities was $2.02 million for the year ended December 31, 2011 compared to $4.35 million cash inflow for the comparable period of 2010. The cash inflow in financing activities during the year of 2011 mainly consisted of proceeds of $2.02 million from common stock and warrants issued in a series of private placements. The net cash inflow in financing activities during the year of 2010 mainly consisted of proceeds of $4.32 million from common stock and warrants issued in another private placement.

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang Pharmaceutical Co., Ltd.  For more information, please visit

Yue Kang (Venus)
+86 451-8835-5530
+86 15846588061 

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials
2. Weikang Bio-Technology to Present at Rodman & Renshaw Annual China Investment Conference
3. Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List
4. Weikang Bio-Technology Expects to Report Fiscal 2010 Revenue of $77.8 Million and Net Income of $31.2 Million or $1.04 Earnings per Share
5. Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
6. Weikang Bio-Technology to Present at Global Hunter 2010 China Conference on July 13, 2010
7. Weikang Bio-Technology Announces Filing for NASDAQ Listing
8. Weikang Bio-Technology Reports First Quarter 2010 Financial Results
9. Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
10. Huntzinger Management Group, Inc., (HMG) Further Invests in Healthcare Industrys "90 Percent"
11. Leading Financial Analyst Group Estimates 5-Year Revenue for HRID at $42MM
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015 Eli Lilly and Company ... square feet and approximately 50 new jobs to its research ... New York, New York . ... 2016, this space will include a translational immuno-oncology hub and ... opportunities for collaborative access to cutting-edge drug discovery capabilities, including ...
(Date:10/9/2015)... 9, 2015 Ansun BioPharma announced a presentation ... America ) regarding the compassionate use of DAS181 under ... respirator who was co-infected with influenza and parainfluenza (Abstract ... therapy, O 2 requirement was reduced and the ... to go off the respirator on day 5. Between ...
(Date:10/9/2015)... , Suiza, October 9, 2015 El ,JCA-Mauvernay ... Yutaka Kondo y Junko Takita    ... otorgado a los doctores Yutaka Kondo y ... ,JCA-Mauvernay Award 2015, se ha otorgado a los doctores ...    ™ , una compañía biofarmacéutica global con sede enSuiza, ...
Breaking Medicine Technology:
... NEW YORK, Sept. 12, 2011 A revolutionary new ... other technology - - the VivoSight® Optical Coherence ... to dermatologists in the U.S. for the first time. ... skin surface instantly, providing additional information which will allow ...
... Sept. 12, 2011 Intarcia Therapeutics, Inc. announced ... ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) ... the 47th Annual Meeting of the European Association ...  All three presentations are scheduled for Wednesday, September ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... The sixth annual cost ... the growth of cybercrime costs for US companies. The New York Times broke down ... With averages showing increases hovering around 20% among the companies surveyed, it only proves ...
(Date:10/10/2015)... ... October 10, 2015 , ... Story Chaser ... It works by reading various classics and inspiring stories and as words drop down ... , The animations are extremely aesthetic and can be interacted with, making it a ...
(Date:10/10/2015)... ... ... Isabel Healthcare will participate in the Cerner Health Conference October 11-14, 2015 ... Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel Healthcare will be featuring ... and consumers to potentially reduce the chance of error. The report suggests that most ...
(Date:10/10/2015)... FLA. (PRWEB) , ... October 10, 2015 , ... In ... has been named the Best Place To Work in Jacksonville, amongst medium-sized companies with ... September 27th and was followed up with a celebratory gala on October 1st. ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American ... Dean for Graduate Medical Education J. Michael Finley, DO, as the recipient of ... selected for his impact on graduate medical education opportunities for osteopathic residents, and ...
Breaking Medicine News(10 mins):
... flu outbreak in February in India, the poultry market saw a ... the government assured the people that all the necessary measures are ... the avian flu the sales of chicken and other birds saw ... deaths due to bird flu the sales dips drastically. Every time ...
... of cognitive behavior therapy (CBT) in overcoming depression can ... the University of Pittsburgh School of Medicine. In a ... Journal of Psychiatry, the official journal of the American ... the response to therapy could be a valuable tool ...
... who suffer from severe urinary infection are more likely ... had found a link between acute infections and heart ... infections and clotting in large veins, reported the online ... at the London School of Hygiene and Tropical Medicine ...
... new genes found with breast tumors can predict the outcomes ... the report appearing in he April 1 issue of Clinical ... women at risk for an early relapse of breast cancer. ... discovered as a potential marker of relapse in hormone-receptor positive ...
... from Sheffield University most women still believe one-night stands ... revealed that women of all ages believe that sex ... ,The women community despite achieving liberation still feels ... of desperation or drunkenness. The research which was followed ...
... are still left confused despite making in-depth analysis in ... psychiatric problem that affects the children. ... which is beyond the scientists' control, between 30 percent ... co-existing conditions, so-called comorbidities that make diagnosis and treatment ...
Cached Medicine News:
... Built on the market leading optical performance ... has been optimized for even better views ... system, including a new XHL Xenon Halogen ... cornea and clear, high resolution images of ...
... 2.2 Fr Sur-Catch NT stone retrieval basket raises ... Its unique paired wire design and multi-sizing ... the needs of each patient and procedure. ... for use with the DURTM-8 Elite Ureteroscope and ...
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
... is a minimally invasive, highly effective surgical ... incontinence. GYNECARE TVT is positioned close to ... and when needed, TVT provides tension-free support ... The procedure takes approximately 20 to 30 ...
Medicine Products: